Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma.

Abstract:

:In health, haemostasis and angiogenesis are tightly regulated processes, but may become deregulated in cancer. Recent evidence suggests that platelet activation may link these processes as platelets can release angiogenic factors such as vascular endothelial growth factor (VEGF). Furthermore, inflammation has also been implicated in regulating both coagulation and angiogenesis, possibly by activating platelets directly and increasing, for example, plasma fibrinogen. We hypothesized relationships between plasma markers of the processes in two common forms of cancer. Plasma levels of VEGF (reflecting angiogenesis), soluble P-selectin, (marking platelet activation), tissue factor [TF], fibrinogen and fibrin D-dimer (coagulation markers), and serum levels of IL-6 (inflammation) were measured by ELISA in 30 patients with biopsy-proven breast cancer, 30 patients with biopsy-proven prostate cancer, and 30 age- and sex-matched controls for each group. Prostate specific antigen was also measured in the men. Release of VEGF from IL-6 stimulated platelets was assessed by ELISA. Plasma levels of IL-6 (P <0.02), VEGF, soluble P-selectin, fibrinogen, and fibrin D-dimer (all p <0.01) were significantly raised in breast cancer, whereas VEGF, soluble P-selectin, fibrin D-dimer (all p <0.01) and fibrinogen (p <0.05) were significantly raised in prostate cancer. Significant correlations were found between IL-6 and VEGF (p <0.01), and IL-6 and soluble P-selectin (p = 0.038) in breast cancer. Further experiments demonstrated an in vitro IL-6 induced dose-dependent release of VEGF from platelets. In conclusion, strong relationships between IL6 and VEGF, but not with coagulation or platelet markers, and release of VEGF from IL-6 stimulated platelets, suggest a role for inflammation and platelets in angiogenesis.

journal_name

Thromb Haemost

authors

Caine GJ,Lip GY,Stonelake PS,Ryan P,Blann AD

doi

10.1160/TH03-11-0679

keywords:

subject

Has Abstract

pub_date

2004-07-01 00:00:00

pages

185-90

issue

1

eissn

0340-6245

issn

2567-689X

pii

04070185

journal_volume

92

pub_type

杂志文章
  • The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor.

    abstract::Novel P2Y12 inhibitors are in development to overcome the occurrence of atherothrombotic events associated with poor responsiveness to the widely used P2Y12 inhibitor clopidogrel. Cangrelor is an intravenously administered P2Y12 inhibitor that does not need metabolic conversion to an active metabolite for its antiplat...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH09-06-0367

    authors: Bouman HJ,van Werkum JW,Rudez G,Leebeek FW,Kruit A,Hackeng CM,Ten Berg JM,de Maat MP,Ruven HJ

    更新日期:2010-02-01 00:00:00

  • High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO).

    abstract::The haematopoietic hormone erythropoietin (EPO) has neuroprotective properties and is currently being explored for treatment of stroke and other neurological disorders. Short-term, high-dose treatment with EPO seems to improve neurological function of stroke patients but may be associated with increased thrombotic ris...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH07-03-0208

    authors: Kirkeby A,Torup L,Bochsen L,Kjalke M,Abel K,Theilgaard-Monch K,Johansson PI,Bjørn SE,Gerwien J,Leist M

    更新日期:2008-04-01 00:00:00

  • A new genetic fibrinogen variant (fibrinogen Erfurt I). Structurally characterized by an abnormal B beta-chain and present both in plasma and platelets.

    abstract::An abnormal fibrinogen was discovered in the plasma of a clinically asymptomatic woman. This fibrinogen variant was analyzed by high resolution two-dimensional gel electrophoresis and its molecular abnormality established consisting in a slight decrease in molecular mass of the B beta-chains. Analysis of fibrin reveal...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Meyer M,Schellenberg I,Vogel G,Bischoff I

    更新日期:1988-04-08 00:00:00

  • Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis.

    abstract::A congenitally abnormal fibrinogen was isolated from blood of a young man with deep-vein thrombosis. Two other affected members of his family had three episodes of severe arterial thrombosis. The fibrinogen showed a delayed clotting by thrombin, but a normal clotting by Arvin, Reptilase, and prothrombin-staphylocoagul...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Haverkate F,Koopman J,Kluft C,D'Angelo A,Cattaneo M,Mannucci PM

    更新日期:1986-02-28 00:00:00

  • A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers.

    abstract::Activated protein C resistance (APCR) is a major risk factor for venous thromboembolism (VTE). Although the factor V (FV) Leiden mutation accounts for the vast majority of APCR cases, other polymorphisms may contribute to the APCR phenotype. Genetic components of APCR and thrombophilia were investigated by two dinucle...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Mingozzi F,Legnani C,Lunghi B,Scanavini D,Castoldi E,Palareti G,Marchetti G,Bernardi F

    更新日期:2003-06-01 00:00:00

  • Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.

    abstract::LMWH preparations have been proven to be safe and effective in the out-patient management of acute DVT. Although LMWHs are more expensive than unfractionated heparin, the lack of need for laboratory monitoring of LMWHs and their potential for out-patient treatment more than offsets the drug related cost difference and...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,评审

    doi:

    authors: Hirsh J,Crowther M

    更新日期:1997-07-01 00:00:00

  • The role of the factor X activation peptide: a deletion mutagenesis approach.

    abstract::To understand the role of the factor X (fX) activation peptide (AP), a deletion mutagenesis approach was employed. Two single-chain, variant enzymes were generated in which 41 residues were deleted from the AP: fX (des-137-183) and fX(des-137-183;N191A), which lacks a carbohydrate moiety at Asn191 due to an alanine su...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Rudolph AE,Mullane MP,Porche-Sorbet R,Daust HA,Miletich JP

    更新日期:2002-11-01 00:00:00

  • The organomercurial 4-aminophenylmercuric acetate, independent of matrix metalloproteinases, induces dose-dependent activation/inhibition of platelet aggregation.

    abstract::Matrix metalloproteinases (MMPs) play an important role in many biological and pathological processes including tissue remodeling, wound healing, inflammation, atherosclerosis, and cancer. Numerous publications have supported the concept that activated MMP-2 enhances agonist-induced platelet aggregation and activated ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH04-08-0541

    authors: Rosenfeldt MT,Valentino M,Labruzzo S,Scudder L,Pavlaki M,Cao J,Vacirca J,Bahou WF,Zucker S

    更新日期:2005-02-01 00:00:00

  • Functional pool of cyclic adenosine 3',5'-monophosphate in rabbit platelets.

    abstract::Accumulation of the newly formed 14C-cyclic adenosine 3',5'-monophosphate (cyclic AMP) was found in the P1 (1.0) fraction, i.e. a platelet plasma membrane fraction which was obtained from 14C-adenine-labeled platelets. On the other hand, total cyclic AMP as determined simultaneously was located mainly in the platelet ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Hashimoto S

    更新日期:1983-02-28 00:00:00

  • Potent inhibition of angiogenesis by D,L-peptides derived from vascular endothelial growth factor receptor 2.

    abstract::Vascular endothelial growth factor (VEGF) is a potent mitogen for endothelial cells and plays a central role in angiogenesis and vasculogenesis. Therefore, VEGF and its receptors VEGFR-1 and VEGFR-2 are prime targets for anti-angiogenic intervention which is thought to be one of the most promising approaches in cancer...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH03-02-0106

    authors: Piossek C,Thierauch KH,Schneider-Mergener J,Volkmer-Engert R,Bachmann MF,Korff T,Augustin HG,Germeroth L

    更新日期:2003-09-01 00:00:00

  • Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group.

    abstract:BACKGROUND:Patients undergoing surgery for cancer are at high risk for venous thromboembolism (VTE). Agents that selectively inhibit thrombin, such as dermatan sulphate, have potential for a favourable benefit-risk ratio in the prevention of this complication. METHODS:Patients scheduled for elective abdominal, thoraci...

    journal_title:Thrombosis and haemostasis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Di Carlo V,Agnelli G,Prandoni P,Coccheri S,Gensini GF,Gianese F,Mannucci PM

    更新日期:1999-07-01 00:00:00

  • Tridegin, a novel peptidic inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro.

    abstract::Tridegin is a potent inhibitor of factor XIIIa from the leech, Haementeria ghilianii, which inhibits protein cross-linking. It modifies plasmin-mediated fibrin degradation as shown by the absence of D-dimer and approximately halves the time for fibrinolysis. Plasma clots formed in the presence of Tridegin lyse more ra...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Seale L,Finney S,Sawyer RT,Wallis RB

    更新日期:1997-05-01 00:00:00

  • Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions.

    abstract::Platelet activation as a result of vascular injury provokes endothelial cells to respond in a manner which limits or reverses the occlusive consequences of platelet accumulation. If the agonistic forces are strong, platelet accumulation is irreversible. In vitro data from our laboratory have repeatedly demonstrated th...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,评审

    doi:

    authors: Marcus AJ,Safier LB,Broekman MJ,Islam N,Fliessbach JH,Hajjar KA,Kaminski WE,Jendraschak E,Silverstein RL,von Schacky C

    更新日期:1995-07-01 00:00:00

  • Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo.

    abstract::Using gain-of-function factor IX (FIX) for replacement therapy for haemophilia B (HB) is an attractive strategy. We previously reported a high-activity FIX, FIX-Triple (FIX-V86A/E277A/R338A) as a good substitute for FIX-WT (wild-type) in protein replacement therapy, gene therapy, and cell therapy. Here we generated a ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH13-02-0154

    authors: Kao CY,Yang SJ,Tao MH,Jeng YM,Yu IS,Lin SW

    更新日期:2013-08-01 00:00:00

  • Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.

    abstract:BACKGROUND:Measurements of prothrombin fragment 1+2 (F1+2), thrombin antithrombin III complexes (TAT) and D-dimer plasma levels have been proposed as non-invasive screening tests to exclude postoperative deep venous thrombosis (DVT). We investigated the diagnostic efficacy of these coagulation activation markers to rul...

    journal_title:Thrombosis and haemostasis

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Cofrancesco E,Cortellaro M,Corradi A,Ravasi F,Bertocchi F

    更新日期:1998-03-01 00:00:00

  • Animal models of vulnerable plaque. Clinical context and current status.

    abstract::There is increasing recognition of the importance of vulnerable plaque and acute plaque rupture leading to thrombosis, in the pathogenesis of acute coronary syndromes. This is fueling a number of developments, including novel imaging modalities and potential plaque stabilization therapies. However, to date, no animal ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,评审

    doi:10.1160/TH03-06-0374

    authors: Lowe HC,Jang IK,Khachigian LM

    更新日期:2003-11-01 00:00:00

  • Controlled multicenter pilot study of urokinase- heparin and streptokinase in deep vein thrombosis.

    abstract::Thirty-three patients with acute iliofemoral thrombosis were randomly assigned to three treatment groups in a pilot dose-ranging study of thrombolytic therapy in deep vein thrombosis. One group received tissue culture urokinase in a dose of 2,200 I.U./kg/hr, and a second group in a dose of 1,100 I.U./kg/hr following a...

    journal_title:Thrombosis and haemostasis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: van de Loo JC,Kriessmann A,Trübestein G,Knoch K,de Swart CA,Asbeck F,Marbet GA,Schmitt HE,Sewell AF,Duckert F

    更新日期:1983-10-31 00:00:00

  • Kinetic parameters of platelet aggregation as an expression of platelet responsiveness.

    abstract::The kinetics of platelet aggregation induced by collagen and by ADP were studied. The maximum aggregation (deltaLTmax) and the ADP and collagen concentrations required to produce half-maximum aggregation (Kd) were determined using platelets obtained from normal individuals, individuals who ingested aspirin and individ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Rossi EC,Louis G

    更新日期:1977-04-30 00:00:00

  • Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

    abstract::AZD0837 is an investigational oral anticoagulant which is converted to the active form, AR-H067637, a selective direct thrombin inhibitor. The present study, a multicentre, randomised, parallel-group, dose-guiding study, assessed the safety and tolerability of an immediate-release formulation of AZD0837 compared with ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1160/TH09-07-0509

    authors: Olsson SB,Rasmussen LH,Tveit A,Jensen E,Wessman P,Panfilov S,Wåhlander K

    更新日期:2010-03-01 00:00:00

  • Factor II related antigen and antithrombin III levels as indicators of liver failure in consumption coagulopathy.

    abstract::In order to detect impaired synthesis of blood coagulation factors associated to consumption coagulopathy, a simultaneous evaluation of factor II-related antigen (II rAg) and of antithrombin III (AT III) was carried out in 16 patients affected with severe defibrination. An in vitro preliminary study on plasma and seru...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Sié P,Letrenne E,Caranobe C,Genestal M,Cathala B,Boneu B

    更新日期:1982-06-28 00:00:00

  • Anti-thrombotic effects of selective estrogen receptor modulator tamoxifen.

    abstract::Tamoxifen is a known anti-cancer drug and established estrogen receptor modulator. Few clinical studies have earlier implicated the drug in thrombotic complications attributable to lower anti-thrombin and protein S levels in plasma. However, action of tamoxifen on platelet signalling machinery has not been elucidated ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH11-03-0178

    authors: Nayak MK,Singh SK,Roy A,Prakash V,Kumar A,Dash D

    更新日期:2011-10-01 00:00:00

  • Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease.

    abstract::FPA level, fibrinogen turnover rate, and fibrinolytic activity were studied on 18 patients with malignant disease. It was found that the FPA levels were significantly elevated and were correlated with fibrinogen turnover rate (r = 0.74, p less than 0.001) and FDP (r - 0.58, p less than 0.02). Estimated FPA turnover ra...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Yoda Y,Abe T

    更新日期:1981-12-23 00:00:00

  • Pleckstrin homology domains and phospholipid-induced cytoskeletal reorganization.

    abstract::At the moment of hemostasis, the platelet must be able to reorganize its cytoskeleton through a complexly orchestrated signaling cascade that is regulated, in part, by polyphosphoinositides. In the past 6 years, evidence has accumulated that PH domains bind these polyphosphoinositides and play a role in cytoskeletal c...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章,评审

    doi:

    authors: Ma AD,Abrams CS

    更新日期:1999-08-01 00:00:00

  • von Willebrand factor release and P-selectin expression is stimulated by thrombin and trypsin but not IL-1 in cultured human endothelial cells.

    abstract::The stimulated release of von Willebrand factor (vWF) from endothelial cells by secretagogues such as thrombin is associated with the translocation of Weibel-Palade bodies to the cell membrane and the surface expression of P-selectin (also known as GMP 140, PADGEM and CD 62). P-selectin, which is stored in Weibel-Pala...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Collins PW,Macey MG,Cahill MR,Newland AC

    更新日期:1993-08-02 00:00:00

  • Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia: a novel cause of acquired qualitative platelet dysfunction.

    abstract::Platelets from a patient with an acquired hemorrhagic disorder had a severely impaired response to collagen, whereas platelet aggregation to other agonists and coagulations tests were normal. No abnormalities of the patient's platelet membrane glycoproteins (GP) were seen. Treatment of the patient with immunosuppressi...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Deckmyn H,Chew SL,Vermylen J

    更新日期:1990-08-13 00:00:00

  • Activated monocytes capture platelets for heterotypic association in patients with severe carotid artery stenosis.

    abstract::Inflammation and thrombosis, two processes influencing each other, are involved in the pathogenesis of cerebrovascular disease. We showed that in patients with acute ischaemic stroke circulating platelets are activated and exhausted. To identify whether activated haemostasis might be cause or effect, we investigated t...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH09-09-0620

    authors: Jurk K,Ritter MA,Schriek C,Van Aken H,Droste DW,Ringelstein EB,Kehrel BE

    更新日期:2010-06-01 00:00:00

  • Developmental haemostasis. Impact for clinical haemostasis laboratories.

    abstract::Developmental haemostasis is a concept, now universally accepted, introduced by Andrew et al. in the late 1980's. However, coagulation analysers and reagents have changed significantly over the past 15 years. Coagulation testing is known to be sensitive to changes in individual reagents and analysers. We hypothesised ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH05-01-0047

    authors: Monagle P,Barnes C,Ignjatovic V,Furmedge J,Newall F,Chan A,De Rosa L,Hamilton S,Ragg P,Robinson S,Auldist A,Crock C,Roy N,Rowlands S

    更新日期:2006-02-01 00:00:00

  • Measurement of thrombin generation in whole blood--the effect of heparin and aspirin.

    abstract::A technique has been developed to monitor the development of thrombin in freshly collected whole blood in the absence of anticoagulants. It is based on the centrifugal separation of the cellular components from subsamples of blood drawn from non-anticoagulated clotting whole blood which are diluted in buffer containin...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:

    authors: Kessels H,Béguin S,Andree H,Hemker HC

    更新日期:1994-07-01 00:00:00

  • Nuclear factor-κB regulates expression of platelet phospholipase C-β2 (PLCB2).

    abstract::Phospholipase C (PLC)-β2 (gene PLCB2) is a critical regulator of platelet responses upon activation. Mechanisms regulating of PLC-β2 expression in platelets/MKs are unknown. Our studies in a patient with platelet PLC-β2 deficiency revealed the PLCB2 coding sequence to be normal and decreased platelet PLC-β2 mRNA, sugg...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH15-09-0749

    authors: Mao G,Jin J,Kunapuli SP,Rao AK

    更新日期:2016-10-28 00:00:00

  • Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin.

    abstract::Circulating endotoxin is elevated in sepsis and plays a role in endothelial dysfunction whereas antithrombin is decreased by virtue of its consumption during complex formation with clotting factors and by proteolytic degradation by granulocyte elastase. Dysfunction of endothelium results in enhanced leukocyte rolling ...

    journal_title:Thrombosis and haemostasis

    pub_type: 杂志文章

    doi:10.1160/TH03-03-0184

    authors: Kaneider NC,Förster E,Mosheimer B,Sturn DH,Wiedermann CJ

    更新日期:2003-12-01 00:00:00